drugset / Trial / NCT07332533
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.
Timeline
- Start
- 2025-12-30
- Primary completion
- 2032-06-30
- Completion
- 2032-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | — | Intravenous |
| Subject | KN026 | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |